Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Wall Street Analysts Forecast Growth
Separately, StockNews.com assumed coverage on shares of Summit Therapeutics in a report on Tuesday. They set a "sell" rating on the stock.
Summit Therapeutics Price Performance
Shares of SMMT Stock traded down $0.03 during mid-day trading on Friday, hitting $1.06. The company had a trading volume of 98,390 shares, compared to its average volume of 142,579. Summit Therapeutics has a 52-week low of $0.88 and a 52-week high of $8.39. The stock's 50 day moving average price is $1.02 and its 200-day moving average price is $1.71. The company has a market capitalization of $104.01 million, a P/E ratio of -1.10 and a beta of 1.05.
Summit Therapeutics (NASDAQ:SMMT - Get Rating) last announced its quarterly earnings results on Wednesday, May 11th. The company reported ($0.22) earnings per share for the quarter. Summit Therapeutics had a negative return on equity of 100.17% and a negative net margin of 735.61%. The business had revenue of $5.06 million during the quarter.